HOB Biotech Group Corp.,Ltd (688656.SS)
CNY 102.72
(-1.37%)
CNY 102.72
(-1.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 106.77 Million CNY | 22.01% |
| 2022 | 86.35 Million CNY | -35.43% |
| 2021 | 124.9 Million CNY | 51.12% |
| 2020 | 83.53 Million CNY | -6.21% |
| 2019 | 88.97 Million CNY | 34.08% |
| 2018 | 59.07 Million CNY | 91.8% |
| 2017 | 34.34 Million CNY | 200.67% |
| 2016 | 11.29 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 7.13 Million CNY | -78.63% |
| 2024 Q2 | 33.04 Million CNY | 165.78% |
| 2024 Q1 | 4.15 Million CNY | -52.02% |
| 2023 Q3 | 19.71 Million CNY | -1.43% |
| 2023 FY | - CNY | 22.01% |
| 2023 Q4 | 12.69 Million CNY | -35.64% |
| 2023 Q2 | 20 Million CNY | 199.79% |
| 2023 Q1 | 6.67 Million CNY | 320.69% |
| 2022 FY | - CNY | -35.43% |
| 2022 Q3 | 23.87 Million CNY | 110.49% |
| 2022 Q2 | 11.34 Million CNY | -29.56% |
| 2022 Q1 | 16.1 Million CNY | 23.12% |
| 2022 Q4 | -3.02 Million CNY | -112.66% |
| 2021 FY | - CNY | 51.12% |
| 2021 Q4 | 13.07 Million CNY | -62.62% |
| 2021 Q3 | 34.98 Million CNY | -6.52% |
| 2021 Q2 | 37.42 Million CNY | 151.07% |
| 2021 Q1 | 14.9 Million CNY | -40.14% |
| 2020 FY | - CNY | -6.21% |
| 2020 Q4 | 24.9 Million CNY | -12.9% |
| 2020 Q3 | 28.59 Million CNY | 912.86% |
| 2020 Q1 | 20.36 Million CNY | 49.35% |
| 2020 Q2 | 2.82 Million CNY | -86.14% |
| 2019 FY | - CNY | 34.08% |
| 2019 Q4 | 13.63 Million CNY | -47.85% |
| 2019 Q3 | 26.15 Million CNY | -64.39% |
| 2019 Q2 | 73.43 Million CNY | 39.99% |
| 2019 Q1 | 52.46 Million CNY | 0.0% |
| 2018 FY | - CNY | 91.8% |
| 2017 FY | - CNY | 200.67% |
| 2016 FY | - CNY | 0.0% |